Caris Life Sciences Swings to $82M Q4 Profit, Revenue Doubles, Crushing Estimates
CAI sits 19% above its 52-week low of $17.15.
Summary
Caris Life Sciences reported a significant beat for its fourth-quarter results, swinging to a net income of $82 million, or $0.28 per share, compared to a loss in the prior year. Revenue more than doubled to $292.9 million, substantially exceeding analyst expectations of $240.4 million. These strong top and bottom-line beats, driven by a near tripling of molecular-profiling-services revenue, indicate robust operational performance and market demand. The positive surprise is likely to bolster investor confidence and could lead to upward revisions in analyst models. The company also provided 2026 revenue guidance of $1 billion to $1.02 billion, which aligns with Wall Street's current expectations, suggesting continued growth.
At the time of this announcement, CAI was trading at $20.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $17.15 to $42.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.